BridgeBio Pharma’s Neil Kumar proposes 34,980-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. director and officer Neil Kumar reported a proposed sale of 34,980 common shares, with an approximate market value of $2,686,464; the approximate sale date is November 18, 2026. The shares were acquired from the issuer as restricted stock units on November 16, 2026. The notice lists May 13, 2026, as the Rule 10b5-1 plan adoption date.
The past-three-months sales list includes Neil Kumar’s sale of 36,236 shares on November 16 for gross proceeds of $2,803,216.96, and 10b5-1 sales attributed to Kumar Haldea Family Irrevocable Tru/T/A Dtd 05/18/2019: 10,000 shares on September 17 and 10,000 on August 19.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.